Novel Techniques of Personalized Medicine for Cancer Treatment
Dr. Amit Joshi
Department of Biochemistry, Kalinga University, Naya Raipur, CG, India-492101
Cancer is a complex and heterogeneous disease that affects millions of people worldwide. Traditional cancer treatments, such as chemotherapy and radiation therapy, have been effective in some cases, but they often result in severe side effects and may not be suitable for every patient. In recent years, personalized medicine has emerged as a promising approach to cancer treatment, offering tailored therapies based on an individual’s unique genetic makeup and the specific characteristics of their tumor. In this article, we will explore some of the novel techniques in personalized medicine that are revolutionizing cancer treatment.
Genomic profiling involves analyzing the genetic material of a patient’s tumor to identify specific mutations or alterations that are driving cancer growth. This technique enables oncologists to develop targeted therapies that directly inhibit the molecular pathways responsible for tumor development. By understanding the unique genomic profile of each patient, physicians can determine the most effective treatment options and avoid unnecessary therapies that may be ineffective or cause adverse reactions.
Traditionally, tumor biopsies involved invasive procedures to extract tissue samples. However, liquid biopsies have emerged as a non-invasive alternative for cancer diagnosis and monitoring. Liquid biopsies involve the analysis of various biomarkers, including circulating tumor cells (CTCs), cell-free DNA, and exosomes, which are released by tumors into the bloodstream. These biomarkers provide valuable information about the genetic mutations, tumor heterogeneity, and treatment response, allowing physicians to make informed decisions regarding personalized treatment plans.
Immunotherapy has revolutionized cancer treatment by harnessing the body’s immune system to fight cancer cells. This approach involves the administration of immune checkpoint inhibitors, monoclonal antibodies, or adoptive cell therapies that enhance the immune response against tumors. Recent advancements in immunotherapy have focused on identifying predictive biomarkers, such as programmed cell death ligand-1 (PD-L1) expression or tumor mutational burden, to select patients who are more likely to respond to these treatments. By tailoring immunotherapies to individual patients, personalized medicine is maximizing treatment efficacy while minimizing potential side effects.
Pharmacogenomics is the study of how an individual’s genetic makeup influences their response to drugs. By analyzing a patient’s genetic variants, pharmacogenomics helps identify genetic markers that determine drug metabolism, efficacy, and potential adverse reactions. This knowledge allows physicians to prescribe medications that are most likely to be effective and well-tolerated by the patient, improving treatment outcomes and reducing the risk of toxicities. Personalized medicine utilizes pharmacogenomics to optimize cancer treatment plans and minimize the trial-and-error approach that often accompanies standard chemotherapy regimens.
Artificial Intelligence and Machine Learning:
Artificial intelligence (AI) and machine learning (ML) algorithms have gained significant attention in the field of personalized medicine. These technologies analyze large volumes of patient data, including genomic information, clinical records, and treatment outcomes, to identify patterns and make predictions. By leveraging AI and ML, oncologists can make more accurate prognoses, develop personalized treatment plans, and discover novel drug targets. Additionally, these techniques aid in the identification of potential drug combinations and the development of clinical decision support systems, facilitating precision medicine implementation in routine clinical practice.
Personalized medicine holds great promise for the future of cancer treatment. The integration of novel techniques such as genomic profiling, liquid biopsies, immunotherapy, pharmacogenomics, and AI/ML algorithms allows oncologists to tailor treatment plans based on the unique characteristics of each patient and their tumor.
Lemjabbar-Alaoui, H., Hassan, O. U., Yang, Y. W., & Buchanan, P. (2015). Lung cancer: Biology and treatment options. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1856(2), 189-210.
Bardeesy, N., & DePinho, R. A. (2002). Pancreatic cancer biology and genetics. Nature Reviews Cancer, 2(12), 897-909.
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014). Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Advanced drug delivery reviews, 66, 2-25.
Ruddon, R. W. (2007). Cancer biology. Oxford University Press.
van Jaarsveld, M. T., Helleman, J., Berns, E. M., & Wiemer, E. A. (2010). MicroRNAs in ovarian cancer biology and therapy resistance. The international journal of biochemistry & cell biology, 42(8), 1282-1290.
Taheriazam, A., Abad, G. G. Y., Hajimazdarany, S., Imani, M. H., Ziaolhagh, S., Zandieh, M. A., … & Hushmandi, K. (2023). Graphene oxide nanoarchitectures in cancer biology: Nano-modulators of autophagy and apoptosis. Journal of Controlled Release, 354, 503-522.
Murakumo, Y., Sakurai, Y., Kato, T., Hashimoto, H., & Ichinoe, M. (2023). REV7 in Cancer Biology and Management. Cancers, 15(6), 1721.
Kalinga Plus is an initiative by Kalinga University, Raipur. The main objective of this to disseminate knowledge and guide students & working professionals.
This platform will guide pre – post university level students.
Pre University Level – IX –XII grade students when they decide streams and choose their career
Post University level – when A student joins corporate & needs to handle the workplace challenges effectively.
We are hopeful that you will find lot of knowledgeable & interesting information here.